Healthy and pathological visual aging in a French follow-up cohort study
Détails
ID Serval
serval:BIB_E0279268FBDA
Type
Actes de conférence (partie): contribution originale à la littérature scientifique, publiée à l'occasion de conférences scientifiques, dans un ouvrage de compte-rendu (proceedings), ou dans l'édition spéciale d'un journal reconnu (conference proceedings).
Sous-type
Abstract (résumé de présentation): article court qui reprend les éléments essentiels présentés à l'occasion d'une conférence scientifique dans un poster ou lors d'une intervention orale.
Collection
Publications
Institution
Titre
Healthy and pathological visual aging in a French follow-up cohort study
Titre de la conférence
2019 ARVO Annual Meeting. Vancouver
Organisation
2019 ARVO Annual Meeting. Vancouver
Adresse
2019 ARVO Annual Meeting. Vancouver, BC, Canada
Statut éditorial
Publié
Date de publication
28/04/2019
Peer-reviewed
Oui
Volume
60
Pages
5915
Langue
anglais
Notes
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 5915.
Résumé
Purpose : Visual aging leads to multiscale changes, from the structures of the eye to sensory transduction, neural transmission, and perception. Also, visuo-cognitive alterations impact visual perception, as demonstrated in divided-attention and visuo-spatial tasks. The French cohort study SilverSight assesses anatomic and functional changes induced by healthy and pathological visual aging, both cross-sectionally and longitudinally. The goal is to understand the relationships between retinal cellular changes (e.g., anatomical and physiological modifications measured with high-resolution adaptive optics retina imaging) and visual symptoms, to identify functional biomarkers of normal and pathological aging.
Methods : The SilverSight cohort targets a population of 400 voluntary participants: 350 healthy subjects and 50 AMD patients. Notably, all enrolled participants undergo a deep multidimensional screening (Figure 1), involving ophthalmological, visual, audio-vestibular, sensorimotor, cognitive, and neuropsychological examinations. We also administer a series of standardized questionnaires and patient-reported outcomes to quantify vision related quality of life and autonomy. All clinical and functional measures are conducted at the National Eye Hospital CHNO des Quinze-Vingts, Paris. The longitudinal follow-up of the SilverSight cohort study is done on a yearly basis.
Results : Since 2015, 364 subjects were screened. Healthy participants are distributed across 3 age groups: 18-40yo (N=140), 41-64yo (N=60), and >65yo (N=158). 25 early- and 25 intermediate-stage AMD patients, as defined by the AREDS grades 2-5 and grades 6-9 in the enrollment eye, are being screened. All data are centralized in a connected anonymized database (eCRF SilverSight), made available for multicenter cohort studies.
Conclusions : The multidimensional screening realized by the SilverSight follow-up cohort study provides a unique database to better understanding the impact of aging on vision and has the potential to uncover cross-causal functional signatures of pathogenic aging mechanisms.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.
Methods : The SilverSight cohort targets a population of 400 voluntary participants: 350 healthy subjects and 50 AMD patients. Notably, all enrolled participants undergo a deep multidimensional screening (Figure 1), involving ophthalmological, visual, audio-vestibular, sensorimotor, cognitive, and neuropsychological examinations. We also administer a series of standardized questionnaires and patient-reported outcomes to quantify vision related quality of life and autonomy. All clinical and functional measures are conducted at the National Eye Hospital CHNO des Quinze-Vingts, Paris. The longitudinal follow-up of the SilverSight cohort study is done on a yearly basis.
Results : Since 2015, 364 subjects were screened. Healthy participants are distributed across 3 age groups: 18-40yo (N=140), 41-64yo (N=60), and >65yo (N=158). 25 early- and 25 intermediate-stage AMD patients, as defined by the AREDS grades 2-5 and grades 6-9 in the enrollment eye, are being screened. All data are centralized in a connected anonymized database (eCRF SilverSight), made available for multicenter cohort studies.
Conclusions : The multidimensional screening realized by the SilverSight follow-up cohort study provides a unique database to better understanding the impact of aging on vision and has the potential to uncover cross-causal functional signatures of pathogenic aging mechanisms.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.
Site de l'éditeur
Création de la notice
05/07/2021 15:21
Dernière modification de la notice
09/07/2021 6:37
Données d'usage
